case_id,count,combos,patient_info,document_name,Q2_baseline,Q2_rag,Q2_gt
Case11855,4,"['top1_10retrieve', 'top1_30retrieve', 'top3_10retrieve', 'top3_30retrieve']","The patient is a 14-year-old being evaluated by a developmental pediatrician for a congenital anomaly affecting a single organ system with concern for an underlying genetic etiology, and chromosomal microarray (CMA) is being ordered to assess for copy number variants associated with developmental disorders; Fragile X testing was previously performed and was nondiagnostic. There is a family history notable for a maternal aunt with triple-negative breast cancer, which was discussed as part of the risk assessment during pre-test counseling. Pre-test counseling was completed with a genetic specialist and plans for post-test follow-up were made, and testing will be pursued with coverage through UHC.",United Healthcare_chromosome-microarray-testing.pdf,Yes,Not Specified,Not Specified
Case12834,4,"['top1_10retrieve', 'top1_30retrieve', 'top3_10retrieve', 'top3_30retrieve']","The patient is a 16-year-old referred by a developmental pediatrician for evaluation of a complex neurodevelopmental disorder affecting at least one organ system, and chromosomal microarray (CMA) testing has been ordered although the requisition specifies a tumor-type rather than a germline assay; prior Fragile X testing was nondiagnostic. There is a family history notable for a maternal uncle with a movement disorder described as dystonia and ataxia, genetic counseling is not documented in the record, and testing will be billed through Cigna.",Cigna_MOL.TS_.344.A_Chromosomal_Microarray_Solid_Tumors_eff01.01.2025_pub09.11.2024_0.pdf,Yes,Not Specified,Not Specified
Case16246,3,"['top1_30retrieve', 'top3_10retrieve', 'top3_30retrieve']","The patient is a 35-year-old woman with a personal history of breast cancer who meets criteria for hereditary testing because her diagnosis occurred before age 50, and she is being referred by her gynecologist for BRCA1 and BRCA2 testing with coverage through UHC; she reports a family history notable for an uncle with pancreatic cancer, prior karyotype testing was performed and was nondiagnostic, and no pre-test genetic counseling has been conducted.",United Healthcare_genetic-testing-hereditary-cancer.pdf,Yes,Not Specified,Not Specified
Case3677,3,"['top1_10retrieve', 'top1_30retrieve', 'top3_30retrieve']","She is a 46-year-old woman with a personal history of breast cancer who is undergoing BRCA1/2 testing because of a close relative with pancreatic cancer and multiple other primary solid tumors on the same side of the family; prior chromosomal microarray (CMA) testing was nondiagnostic. The patient was referred by a nurse practitioner and completed pre-test genetic counseling with plans for post-test follow-up, and testing will be billed to UHC. Her family history is notable for a mother with pancreatic cancer and at least two additional affected relatives on the maternal side.",United Healthcare_genetic-testing-hereditary-cancer.pdf,Yes,Not Specified,Not Specified
Case6478,2,"['top1_10retrieve', 'top3_30retrieve']","A 52-year-old man with metastatic prostate cancer is being referred by his general practitioner for germline BRCA1 and BRCA2 testing because of a family history notable for a father with pancreatic cancer; he has had no prior genetic testing, pre-test genetic counseling was not completed, and testing is being pursued with coverage through UHC to inform therapeutic options and cascade testing for at-risk relatives with plans for post-test counseling and oncology follow-up once results are available.",United Healthcare_genetic-testing-hereditary-cancer.pdf,Yes,Not Specified,Not Specified
Case3592,2,"['top1_10retrieve', 'top3_10retrieve']","The patient is a neonate evaluated by a developmental pediatrician for unexplained epileptic encephalopathy with neonatal onset and no prior epilepsy multigene panel testing; chromosomal microarray (CMA) testing for developmental disorders is being requested. A prior chromosomal microarray was nondiagnostic. There is a family history of an older sibling with unexplained developmental regression unrelated to autism or epilepsy. Pre-test counseling was discussed with a genetic specialist and post-test follow-up is planned, and testing is being submitted with coverage through Cigna.",Cigna_MOL.TS_.150A_CMA_for_Developmental_Disorders_and_Prenatal_Diagnosis_eff01.01.2025_pub09.10.2024_1.pdf,Yes,Not Specified,Not Specified
Case15820,1,['top1_30retrieve'],"The patient is a 31-year-old adult followed by neurology for developmental delay and intellectual disability without a suspected specific syndrome, and chromosomal microarray (CMA) has been ordered to evaluate for underlying copy number variants; no prior genetic testing has been reported, and the patient has completed multiple pre-test counseling sessions with a genetic counselor with plans for post-test follow-up, with insurance coverage through Cigna, and a pertinent family history of a mother who was diagnosed with breast cancer before age 50.",Cigna_MOL.TS_.150A_CMA_for_Developmental_Disorders_and_Prenatal_Diagnosis_eff01.01.2025_pub09.10.2024_1.pdf,Yes,Not Specified,Not Specified
Case17929,1,['top3_10retrieve'],"Referred by a neurologist, a 7-year-old child covered by UHC is being evaluated for a major abnormality affecting at least one organ system and tumor chromosomal microarray (CMA) testing has been requested to assess for genomic imbalance after prior karyotype testing was nondiagnostic, the family history is notable for a known BRCA1/2 pathogenic variant identified in the mother and a maternal aunt, and the child has had multiple pretest counseling sessions with a genetic counselor with plans for post-test follow-up with neurology and genetics.",United Healthcare_chromosome-microarray-testing.pdf,Yes,Not Specified,Not Specified
Case2211,1,['top3_10retrieve'],"A 21-year-old patient is referred by a general practitioner for BRCA1 and BRCA2 (breast cancer susceptibility) testing because of a personal history of a primary solid tumor and reports of at least two additional affected blood relatives on the same side of the family; the patient states that the mother carries a known BRCA2 pathogenic variant. No prior genetic testing has been performed, and pre-test counseling was completed with a genetic specialist with plans for post-test follow-up. Testing is being requested through UHC to clarify hereditary cancer risk and to guide management for this young adult.",United Healthcare_genetic-testing-hereditary-cancer.pdf,Yes,Not Specified,Not Specified
Case18868,1,['top3_30retrieve'],"The patient is a 41-year-old with a diagnosis of primary peritoneal carcinoma who was evaluated by a medical geneticist and for whom whole genome sequencing (WGS) has been ordered to assess for an underlying hereditary cancer predisposition; prior karyotype testing was nondiagnostic. Her mother reportedly has a persistent and severe hematologic disorder, which raised concern for a heritable syndrome affecting cancer and hematologic risk. Coverage is through Cigna, and there was no documented record of pre-test genetic counseling in the materials provided.",Cigna_MOL.TS_.306.C_Whole_Genome_Sequencing_Cigna_eff01.01.2025_pub09.10.2024.pdf,Yes,Not Specified,Not Specified
Case5303,1,['top1_10retrieve'],"The 37-year-old patient was referred by neurology for BRCA1 and BRCA2 testing in the setting of a major abnormality affecting at least one organ system and a family history notable for a brother who died suddenly and unexpectedly before age 35; no prior genetic testing has been performed and no pre-test genetic counseling was conducted, and the patient has coverage through UHC.",United Healthcare_genetic-testing-hereditary-cancer.pdf,Yes,Not Specified,Not Specified
Case9408,1,['top1_30retrieve'],"The 17-year-old patient is undergoing whole exome sequencing (WES) at the request of a medical geneticist for evaluation of epileptic encephalopathy with onset before three years of age; chromosomal microarray (CMA) testing was previously performed and was nondiagnostic. There is a family history of a persistent and severe immunologic or hematologic disorder in the patient's mother, and pre-test counseling was completed with plans for post-test follow-up with a genetic counselor. Testing will be submitted to Blue Cross Blue Shield Federal Employee Program (FEP) for coverage.",BCBS_FEP_204102 Whole Exome and.pdf,Yes,Not Specified,Not Specified
